Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

7.3%

8 terminated out of 110 trials

Success Rate

85.2%

-1.3% vs benchmark

Late-Stage Pipeline

29%

32 trials in Phase 3/4

Results Transparency

20%

9 of 46 completed with results

Key Signals

9 with results85% success

Data Visualizations

Phase Distribution

88Total
Not Applicable (48)
P 1 (2)
P 2 (6)
P 3 (11)
P 4 (21)

Trial Status

Completed46
Unknown32
Recruiting11
Terminated8
Enrolling By Invitation4
Not Yet Recruiting4

Trial Success Rate

85.2%

Benchmark: 86.5%

Based on 46 completed trials

Clinical Trials (110)

Showing 20 of 20 trials
NCT07545148Not Yet Recruiting

Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life

NCT06351683Phase 2Terminated

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

NCT05878951Phase 2Recruiting

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT06389838Not ApplicableCompleted

RCT on Multimodal Self-treatment for Women With Incontinence Using a Digital Health Application

NCT06341673Not ApplicableRecruitingPrimary

Impact of TTNS on Bladder Symptoms Among People With MS, A RCT

NCT05977634Not ApplicableActive Not Recruiting

Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder

NCT06198439Not ApplicableCompleted

rTMS in Overactive Bladder

NCT07171424Not ApplicableEnrolling By InvitationPrimary

Moving Beyond p-Values: MCID for OAB-V8 8 and ICIQ-SF in Patients With OAB

NCT05308979Phase 4Completed

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT07416968Phase 4Recruiting

Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

NCT06438861Not ApplicableWithdrawnPrimary

Role of Combination Therapy in Women With Refractory Overactive Bladder

NCT05895045Not ApplicableRecruiting

Yoga for Treatment of Overactive Bladder in Pediatric Patients

NCT03952299Phase 3RecruitingPrimary

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT04873037Not ApplicableRecruitingPrimary

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

NCT06143397Not ApplicableCompleted

Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.

NCT06094543Not ApplicableRecruitingPrimary

Improving Overactive Bladder Treatment Access and Adherence

NCT05309993Not ApplicableTerminated

INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

NCT06212661Enrolling By Invitation

Migraine Medication Effects on Urinary Symptoms

NCT06546189Not ApplicableRecruitingPrimary

Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial

NCT07184307Not ApplicableRecruitingPrimary

Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial

Scroll to load more

Research Network

Activity Timeline